Acercus Entitled To Commercialize UriVarx in Canada

Acercus pharmaceuticals declare exclusive distributor and license agreement with Innovus Pharmaceuticals. UriVarx is a Natural Health Product (NHP) that alleviates symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia testimony to the fact that the product was recently sanctioned by Health Canada and will be offered over-the-counter to Canadians afflicted with the same. It is to be noted that nearly 1 in 5 Canadians over the age of 35 encounter overactive bladder symptoms. The current methods of treatment witness multiple adverse effects on their bodies.

Innovus will monitor the manufacturing of UriVarx and will receive a supply price for the product as stated in the agreement.

Tricia Symmes, Chief Operating Officer of Acerus. Stated “This is a great partnership for Acerus as UriVarx is well-aligned with our strategy of optimizing our existing presence in urology and maintaining an active dialogue with Canadian patients. As UriVarx is already approved by Health Canada; the Acerus team expects to launch the product in the second half of 2018, thereby potentially generating meaningful revenues this year.”

Bassam Damaj, President and Chief Executive Officer of Innovus, mentioned: “We are confident that Acerus Pharmaceuticals is an excellent partner to bring UriVarx to the Canadian market, with an established dedicated presence in Canadian men and women’s health as well as in urology.”